Pekin Hardy Strauss, Inc. Ardelyx, Inc. Transaction History

Pekin Hardy Strauss, Inc.

$919 Million
Q3 2025

A detailed history of Pekin Hardy Strauss, Inc. transactions in Ardelyx, Inc. stock. As of the latest transaction made, Pekin Hardy Strauss, Inc. holds 402,230 shares of ARDX stock, worth $2.36 Million. This represents 0.24% of its overall portfolio holdings.

Number of Shares

402,230

Previous 463,430 13.21%

Holding current value

$2.36 Million

Previous $1.82 Million 22.25%

% of portfolio

0.24%

Previous 0.22%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 07, 2025	SELL	$3.92 - $6.64 $239,904 - $406,368	-61,200 Reduced 13.21%	402,230 $2.22 Million
Q2 2025 Aug 06, 2025	BUY	$3.28 - $5.51 $983 - $1,653	300 Added 0.06%	463,430 $1.82 Million
Q1 2025 Apr 29, 2025	SELL	$4.91 - $6.36 $416,515 - $539,518	-84,830 Reduced 15.48%	463,130 $2.27 Million
Q4 2024 Feb 03, 2025	BUY	$4.49 - $6.85 $6,959 - $10,617	1,550 Added 0.28%	547,960 $2.83 Million
Q3 2024 Nov 12, 2024	BUY	$5.28 - $7.57 $77,880 - $111,657	14,750 Added 2.77%	546,410 $3.76 Million

Q2 2024 Aug 09, 2024	SELL	$5.89 - $9.31 $64,790 - $102,410	-11,000 Reduced 2.03%	531,660 $3.94 Million
Q1 2024 May 02, 2024	SELL	$6.05 - $9.74 $1.38 Million - $2.23 Million	-228,707 Reduced 29.65%	542,660 $3.96 Million
Q4 2023 Feb 05, 2024	SELL	$3.29 - $6.64 $171,589 - $346,309	-52,155 Reduced 6.33%	771,367 $4.78 Million
Q3 2023 Nov 07, 2023	SELL	$3.3 - $4.83 $1.22 Million - $1.79 Million	-370,600 Reduced 31.04%	823,522 $3.36 Million
Q2 2023 Aug 08, 2023	SELL	$3.23 - $4.95 $154,232 - $236,362	-47,750 Reduced 3.85%	1,194,122 $4.05 Million
Q1 2023 May 08, 2023	SELL	$2.68 - $4.79 $1.15 Million - $2.05 Million	-427,876 Reduced 25.63%	1,241,872 $5.95 Million
Q4 2022 Feb 13, 2023	SELL	$1.22 - $2.85 $341,008 - $796,617	-279,515 Reduced 14.34%	1,669,748 $4.76 Million
Q3 2022 Nov 09, 2022	BUY	$0.59 - $1.44 $125,733 - $306,875	213,108 Added 12.27%	1,949,263 $2.32 Million
Q2 2022 Aug 05, 2022	BUY	$0.51 - $1.17 $1,537 - $3,527	3,015 Added 0.17%	1,736,155 $1.02 Million
Q1 2022 May 13, 2022	BUY	$0.65 - $1.18 $148,170 - $268,986	227,955 Added 15.14%	1,733,140 $1.85 Million
Q4 2021 Feb 08, 2022	BUY	$0.86 - $1.7 $204,440 - $404,127	237,722 Added 18.76%	1,505,185 $1.66 Million
Q3 2021 Nov 12, 2021	BUY	$1.27 - $8.17 $158,115 - $1.02 Million	124,500 Added 10.89%	1,267,463 $1.67 Million
Q2 2021 Aug 12, 2021	SELL	$6.55 - $8.98 $3.23 Million - $4.43 Million	-493,767 Reduced 30.17%	1,142,963 $8.66 Million
Q1 2021 May 13, 2021	BUY	$6.1 - $7.69 $362,498 - $456,985	59,426 Added 3.77%	1,636,730 $10.8 Million
Q4 2020 Feb 11, 2021	SELL	$5.05 - $7.1 $725,669 - $1.02 Million	-143,697 Reduced 8.35%	1,577,304 $10.2 Million
Q3 2020 Nov 12, 2020	BUY	$5.25 - $7.08 $863,346 - $1.16 Million	164,447 Added 10.56%	1,721,001 $9.04 Million
Q2 2020 Aug 10, 2020	SELL	$5.37 - $8.11 $1.37 Million - $2.08 Million	-255,963 Reduced 14.12%	1,556,554 $10.8 Million
Q1 2020 May 11, 2020	SELL	$4.35 - $8.79 $1.35 Million - $2.73 Million	-310,075 Reduced 14.61%	1,812,517 $10.3 Million
Q4 2019 Feb 12, 2020	BUY	$4.23 - $8.29 $346,140 - $678,370	81,830 Added 4.01%	2,122,592 $15.9 Million
Q3 2019 Nov 12, 2019	SELL	$2.15 - $6.28 $693,185 - $2.02 Million	-322,412 Reduced 13.64%	2,040,762 $9.59 Million
Q2 2019 Aug 12, 2019	SELL	$2.49 - $3.73 $869,333 - $1.3 Million	-349,130 Reduced 12.87%	2,363,174 $6.36 Million
Q1 2019 May 14, 2019	BUY	$1.88 - $3.35 $136,021 - $242,379	72,352 Added 2.74%	2,712,304 $7.59 Million
Q4 2018 Feb 12, 2019	BUY	$1.66 - $4.16 $2.72 Million - $6.83 Million	1,641,037 Added 164.28%	2,639,952 $4.73 Million
Q3 2018 Nov 02, 2018	BUY	$3.75 - $4.65 $3.75 Million - $4.64 Million	998,915 New	998,915 $4.35 Million

Others Institutions Holding ARDX

# of Institutions

248

Shares Held

160M

Call Options Held

697K

Put Options Held

1.61M

View Full List

About ARDELYX, INC.

Ticker ARDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 154,636,000
Market Cap $908M
Description
Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel synd...

More about ARDX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Pekin Hardy Strauss, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Pekin Hardy Strauss, Inc. with notifications on news.

Account

Pekin Hardy Strauss, Inc. Ardelyx, Inc. Transaction History